Right Ventricular Function During Liver Transplantation as Assessed by Transesophageal Echocardiography.

• Conditions: Liver Transplant; Complications

• Registration Number: NCT03459924
• Lead Sponsor: Universidade Federal do Rio de Janeiro

Brief Summary

Cirrhotic patients undergoing liver transplantation might develop acute transient right ventricular dysfunction, ranging from mild to severe form. More than two decades ago, a number of studies with pulmonary artery catheters looked at this particular issue with controversial results. However, the pulmonary artery catheter as a monitor for right ventricular function (RVF) has several limitations, while the echocardiogram is deemed to be more accurate in this regard. Therefore, we sought to evaluate the RVF with the transesophageal echocardiogram, and particularly whether the RVF significantly varies during this procedure.

Detailed Description

Evaluation of right ventricular function (RVF) during orthotopic liver transplantation (OLT) has been extensively reported with modified pulmonary artery catheters that measure the right ventricular ejection fraction. However, quantitative analysis of RVF using transesophageal echocardiography (TEE) are scarce in this setting.

Methods: Nineteen cirrhotic patients who underwent OLT from April-2012 to April-2013 will be studied. Analysis of echocardiogram-derived parameters routinely used to evaluate ventricular function will be done. In particular, the RVF was quantitatively assessed by two parameters derived from TEE: tricuspid annular plane systolic excursion (TAPSE) and right ventricular fractional area change (RVFAC). Exclusion criteria: pulmonary hypertension, fulminant hepatitis, age less than 18 or greater than 65 years old and cardiopulmonary diseases. All echocardiographic and hemodynamic data set have been collected at 5 stages during the procedure, according to Institutional Protocol: baseline, hepatectomy, anhepatic phase, post-reperfusion, and closure.

Statistical Analysis: One-way ANOVA for repeated measurements will be used if the data have normal distribution, otherwise Friedman test will be used. P\<0.05 is to be considered significant.

Study Timeline

• Study Start: 2018-02-27
• Study First Submitted: 2018-02-27
• Status Verified: 2018-03
• Study First Submitted QC: 2018-03-03
• Last Update Submitted: 2018-03-03
• Study First Posted: 2018-03-09
• Last Update Posted: 2018-03-09
• Primary Completion: 2019-01-01
• Study Completion: 2019-01-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Adult patients who underwent orthotopic liver transplantation from april 2012 to april 2013.

Exclusion Criteria

• Pulmonary hypertension (any type)
• Cardiopulmonary disease (eg: chronic obstructive pulmonary disease (COPD), valvular heart disease, ischemic heart disease)
• Fulminant hepatitis.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Development of new right ventricular dysfunction during liver transplantation	Through study completion, after 1 year of data retrieval and analysis.	Signs of right ventricular dysfunction as assessed by transesophageal echocardiography

Trial Locations

Locations (1)

Federal University of Rio de Janeiro; 🇧🇷 Rio De Janeiro, Brazil